Cocrystal Pharma (COCP) Competitors $1.59 -0.07 (-4.26%) Closing price 03/18/2025 04:00 PM EasternExtended Trading$1.60 +0.00 (+0.31%) As of 03/18/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends COCP vs. CUE, KPTI, BYSI, ENTX, CTOR, PYXS, QNCX, PMVP, MRSN, and VHAQShould you be buying Cocrystal Pharma stock or one of its competitors? The main competitors of Cocrystal Pharma include Cue Biopharma (CUE), Karyopharm Therapeutics (KPTI), BeyondSpring (BYSI), Entera Bio (ENTX), Citius Oncology (CTOR), Pyxis Oncology (PYXS), Quince Therapeutics (QNCX), PMV Pharmaceuticals (PMVP), Mersana Therapeutics (MRSN), and Viveon Health Acquisition (VHAQ). These companies are all part of the "pharmaceutical products" industry. Cocrystal Pharma vs. Cue Biopharma Karyopharm Therapeutics BeyondSpring Entera Bio Citius Oncology Pyxis Oncology Quince Therapeutics PMV Pharmaceuticals Mersana Therapeutics Viveon Health Acquisition Cocrystal Pharma (NASDAQ:COCP) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability. Which has better valuation & earnings, COCP or CUE? Cocrystal Pharma has higher earnings, but lower revenue than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCocrystal PharmaN/AN/A-$17.98M-$1.85-0.86Cue Biopharma$9.53M6.41-$50.73M-$0.90-1.07 Which has more volatility and risk, COCP or CUE? Cocrystal Pharma has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Do analysts prefer COCP or CUE? Cocrystal Pharma currently has a consensus price target of $7.00, indicating a potential upside of 340.25%. Cue Biopharma has a consensus price target of $4.75, indicating a potential upside of 392.23%. Given Cue Biopharma's higher possible upside, analysts clearly believe Cue Biopharma is more favorable than Cocrystal Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor COCP or CUE? In the previous week, Cue Biopharma had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 1 mentions for Cue Biopharma and 0 mentions for Cocrystal Pharma. Cue Biopharma's average media sentiment score of 1.89 beat Cocrystal Pharma's score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Cocrystal Pharma Neutral Cue Biopharma Very Positive Do insiders & institutionals have more ownership in COCP or CUE? 6.7% of Cocrystal Pharma shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 25.6% of Cocrystal Pharma shares are held by insiders. Comparatively, 12.3% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is COCP or CUE more profitable? Cocrystal Pharma has a net margin of 0.00% compared to Cue Biopharma's net margin of -468.02%. Cocrystal Pharma's return on equity of -94.62% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cocrystal PharmaN/A -94.62% -78.24% Cue Biopharma -468.02%-156.38%-88.07% Does the MarketBeat Community favor COCP or CUE? Cue Biopharma received 122 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 77.42% of users gave Cocrystal Pharma an outperform vote while only 52.33% of users gave Cue Biopharma an outperform vote. CompanyUnderperformOutperformCocrystal PharmaOutperform Votes2477.42% Underperform Votes722.58% Cue BiopharmaOutperform Votes14652.33% Underperform Votes13347.67% SummaryCocrystal Pharma and Cue Biopharma tied by winning 8 of the 16 factors compared between the two stocks. Remove Ads Get Cocrystal Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COCP vs. The Competition Export to ExcelMetricCocrystal PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.18M$7.12B$5.74B$8.01BDividend YieldN/A2.77%4.41%4.09%P/E Ratio-0.866.2924.0319.08Price / SalesN/A229.67399.5287.44Price / CashN/A65.6738.1134.64Price / Book0.616.506.824.32Net Income-$17.98M$141.58M$3.19B$247.06M7 Day Performance-2.75%-0.51%-0.23%0.83%1 Month Performance-14.05%-8.15%-0.47%-9.31%1 Year Performance11.97%-5.34%13.30%4.51% Cocrystal Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COCPCocrystal Pharma2.6993 of 5 stars$1.59-4.3%$7.00+340.3%+7.4%$16.18MN/A-0.8610Gap DownCUECue Biopharma4.4227 of 5 stars$1.03-6.4%$5.00+385.4%-51.5%$65.25M$9.53M-1.1460Upcoming EarningsNews CoveragePositive NewsKPTIKaryopharm Therapeutics4.1381 of 5 stars$7.66+11.2%$57.50+650.7%-73.6%$64.50M$145.24M-7.51380Short Interest ↓Positive NewsHigh Trading VolumeBYSIBeyondSpringN/A$1.65-1.2%N/A-39.2%$64.40M$1.88M0.0080Positive NewsGap DownENTXEntera Bio2.323 of 5 stars$1.78-5.8%$10.00+461.8%+42.3%$63.70M$99,000.00-6.8520Analyst ForecastNews CoverageGap UpCTORCitius OncologyN/A$0.89-5.3%$3.00+237.1%N/A$63.68MN/A0.00N/APYXSPyxis Oncology1.7753 of 5 stars$1.07-7.8%$9.20+759.8%-78.4%$63.63M$16.15M-1.0460Upcoming EarningsAnalyst ForecastNews CoverageGap DownQNCXQuince Therapeutics2.3449 of 5 stars$1.44-4.6%$9.50+559.7%+10.9%$63.36MN/A-1.1660News CoveragePMVPPMV Pharmaceuticals2.226 of 5 stars$1.22-0.8%$5.50+350.8%-24.0%$63.36MN/A-1.2250MRSNMersana Therapeutics4.0656 of 5 stars$0.50-7.9%$4.25+748.0%-90.3%$62.47M$40.50M-0.82150Gap DownVHAQViveon Health AcquisitionN/A$11.00flatN/A+611,011.1%$62.26MN/A0.002High Trading Volume Remove Ads Related Companies and Tools Related Companies CUE Competitors KPTI Competitors BYSI Competitors ENTX Competitors CTOR Competitors PYXS Competitors QNCX Competitors PMVP Competitors MRSN Competitors VHAQ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COCP) was last updated on 3/19/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cocrystal Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cocrystal Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
